Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta.

Lin CH, Chien YH, Peng SF, Tsai WY, Tung YC, Lee CT, Chien CC, Hwu WL, Lee NC.

Pediatr Neonatol. 2014 Aug;55(4):306-11. doi: 10.1016/j.pedneo.2013.12.001. Epub 2014 Jan 31.

2.

Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.

Land C, Rauch F, Travers R, Glorieux FH.

Bone. 2007 Mar;40(3):638-44. Epub 2006 Nov 28.

PMID:
17127117
3.

Cyclic pamidronate therapy in children with osteogenesis imperfecta.

Salehpour S, Tavakkoli S.

J Pediatr Endocrinol Metab. 2010 Jan-Feb;23(1-2):73-80.

PMID:
20432809
4.

Bone densitometry in pediatric patients treated with pamidronate.

Grissom LE, Kecskemethy HH, Bachrach SJ, McKay C, Harcke HT.

Pediatr Radiol. 2005 May;35(5):511-7. Epub 2005 Jan 18.

PMID:
15655696
5.

Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age.

Kusumi K, Ayoob R, Bowden SA, Ingraham S, Mahan JD.

J Bone Miner Metab. 2015 Sep;33(5):560-8. doi: 10.1007/s00774-014-0618-2. Epub 2014 Oct 16.

PMID:
25319557
6.

Benefits of pamidronate in children with osteogenesis imperfecta: an open prospective study.

Forin V, Arabi A, Guigonis V, Filipe G, Bensman A, Roux C.

Joint Bone Spine. 2005 Jul;72(4):313-8. Epub 2004 Dec 15.

PMID:
16038843
7.

Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.

Alcausin MB, Briody J, Pacey V, Ault J, McQuade M, Bridge C, Engelbert RH, Sillence DO, Munns CF.

Horm Res Paediatr. 2013;79(6):333-40. doi: 10.1159/000351374. Epub 2013 May 31.

PMID:
23735642
8.

Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.

Andiran N, Alikasifoglu A, Gonc N, Ozon A, Kandemir N, Yordam N.

J Pediatr Endocrinol Metab. 2008 Jan;21(1):63-72.

PMID:
18404974
9.

Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.

DiMeglio LA, Ford L, McClintock C, Peacock M.

Bone. 2004 Nov;35(5):1038-45.

PMID:
15542028
10.

Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.

Atta I, Iqbal F, Lone SW, Ibrahim M, Khan YN, Raza J.

J Coll Physicians Surg Pak. 2014 Sep;24(9):653-7. doi: 09.2014/JCPSP.653657.

PMID:
25233970
11.
12.

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.

Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R.

N Engl J Med. 1998 Oct 1;339(14):947-52.

13.

Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.

Vallo A, Rodriguez-Leyva F, Rodríguez Soriano J.

Acta Paediatr. 2006 Mar;95(3):332-9.

PMID:
16497645
14.

Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta.

Palomo T, Andrade MC, Peters BS, Reis FA, Carvalhaes JT, Glorieux FH, Rauch F, Lazaretti-Castro M.

Calcif Tissue Int. 2016 Jan;98(1):42-8. doi: 10.1007/s00223-015-0061-y. Epub 2015 Sep 21.

PMID:
26387692
15.

Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta.

González E, Pavía C, Ros J, Villaronga M, Valls C, Escolá J.

J Pediatr Endocrinol Metab. 2001 May;14(5):529-33.

PMID:
11393574
16.

Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.

Otaify GA, Aglan MS, Ibrahim MM, Elnashar M, El Banna RA, Temtamy SA.

Osteoporos Int. 2016 Jan;27(1):81-92. doi: 10.1007/s00198-015-3216-9. Epub 2015 Jul 3.

PMID:
26138583
17.
18.

Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.

Shapiro JR, Thompson CB, Wu Y, Nunes M, Gillen C.

Calcif Tissue Int. 2010 Aug;87(2):120-9. doi: 10.1007/s00223-010-9383-y. Epub 2010 Jun 11.

PMID:
20544187
19.

New trends in the treatment of osteogenesis imperfecta type III - own experience.

Jakubowska-Pietkiewicz E, Chlebna-Sokół D.

Ortop Traumatol Rehabil. 2008 Nov-Dec;10(6):593-601. English, Polish.

PMID:
19153548
20.

The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta type V.

Zeitlin L, Rauch F, Travers R, Munns C, Glorieux FH.

Bone. 2006 Jan;38(1):13-20. Epub 2005 Sep 12.

PMID:
16162424

Supplemental Content

Support Center